CA
CASI Pharmaceuticals, Inc.
CASI · NASDAQ
$0.15 +3.08% (+$0.00)
Market Cap $2.25M
P/E Ratio -
Div. Yield -
ROE 358.32%
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.08x
P/FFO N/A
P/B N/A
Growth
78 /100
Growing Book val. growth 15.16%
Rev. growth 118.52%
FCF growth N/A
Profitability
16 /100
Weak Net margin 183.93%
Op. margin 167.98%
FCF margin 0.00%
Quality
44 /100
Average ROE 358.32%
ROA 201.86%
Asset turnover 1.10x
Debt
50 /100
Moderate Int. coverage -31.98x
Net debt/EBITDA -0.34x
Current ratio 0.30x
Stability
48 /100
Moderate Rev. volatility 116.31%
EPS volatility 25.29%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CASI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Cory
Employees
233
Headquarters
Beijing